Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
商品番号 : SMB-74182
| 出版社 | BCC Research |
| 出版年月 | 2025年1月 |
| ページ数 | 150 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,650 |
| 種別 | 英文調査報告書 |
Report Highlights
The global market for liquid biopsy is expected to grow from $4.6 billion in 2024 and is projected to reach $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.
リキッドバイオプシー（液体生検）の世界市場は、2024年の46億ドルから2024年から2029年の予測期間中に23.3%の年平均成長率（CAGR）で成長し、2029年末までに131億ドルに達すると予測されています。
Summary:
Liquid biopsies are a particularly alluring substitute for or addition to tissue biopsies for applications in cancer, transplant medicine and reproductive health. Finding the biomarker that indicates the liquid biopsy’s intended use—tumor (for cancer applications), fetus (for prenatal screening applications) or transplanted organ (for transplant medicine applications) is the goal of a liquid biopsy. A paradigm shift in medicine is brought about by liquid biopsy, which also offers enormous business prospects. These market niches hold great promises for cancer screening and early diagnosis, recurrence monitoring for cancer patients and non-invasive prenatal screening for average-risk populations.
リキッドバイオプシー（液体生検）は、がん、移植医療、生殖医療の分野で組織生検の代替または追加として特に魅力的です。液体生検の目的である腫瘍（がんの場合）、胎児（出生前スクリーニングの場合）、移植臓器（移植医療の場合）を示すバイオマーカーを見つけることが液体生検の目的です。液体生検は医療のパラダイムシフトをもたらし、また膨大なビジネスの可能性も提供します。これらのニッチ市場は、がんのスクリーニングと早期診断、がん患者の再発モニタリング、および平均リスク集団の非侵襲的出生前スクリーニングに大きな可能性を秘めています。
Liquid biopsies offer substantial medical benefits when compared with traditional tissue-based biopsies. These benefits drive the adoption of liquid biopsy in the three major market segments: cancer, reproductive health and organ transplantation. For cancer, tissue biopsy is historically the standard of care. Needles, surgery or endoscopy are often used to perform tissue biopsies. Each of these methods poses potential risks to the patient. For example, a needle biopsy can result in several complications, including hemorrhage, hematoma, pneumothorax, puncture of nearby organs or tissues, infection, needle tract implantation or seeding of tumor cells. In addition, there is often pain and discomfort during a biopsy procedure.
Report Scope
This report provides an in-depth analysis of the global market for liquid biopsy tools, services and diagnostics, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. The report includes an overview of the industry structure and its competitive landscape. Leading market players’ profiles, product offerings, financial information and recent market activities are provided. The report also assesses companies’ business strategies and their effect in the face of the competitive environment. It details the global market based on application, purpose of analysis, biomarker type and platform. Regional analysis includes North America (U.S., Canada, Mexico), Europe (U.K., Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the world (South America, and the Middle East and Africa).
このレポートは、2023年を基準年として、2024年から2029年までの年平均成長率（CAGR）予測を用いた市場推定と動向を含む、液体生検ツール、サービス、診断の世界市場の詳細な分析を提供します。レポートには、業界構造とその競争環境の概要が含まれています。主要な市場プレーヤーのプロファイル、製品提供、財務情報、および最近の市場活動が提供されています。レポートでは、競争環境に直面した企業のビジネス戦略とその効果も評価しています。アプリケーション、分析目的、バイオマーカーの種類、プラットフォームに基づいて、世界市場の詳細を説明します。地域分析には、北米（米国、カナダ、メキシコ）、ヨーロッパ（英国、ドイツ、フランス、スペイン、イタリア、その他のヨーロッパ）、アジア太平洋（中国、インド、日本、その他のアジア太平洋）、その他の地域（南米、中東、アフリカ）が含まれます。
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2023 | ||||||||||||||||
| Forecast period considered | 2024-2029 | ||||||||||||||||
| Base year market size | $3.8 billion | ||||||||||||||||
| Market size forecast | $13.1 billion | ||||||||||||||||
| Growth rate | CAGR of 23.3% for the forecast period of 2024-2029 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | Application, Purpose of Analysis, Biomarker Type, Platform, and Region | ||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and the Rest of the world | ||||||||||||||||
| Countries covered | U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, China, India, Japan, South America, and the Middle East and Africa | ||||||||||||||||
| Key Market Drivers |
| ||||||||||||||||
| Companies studied |
| ||||||||||||||||
Report Includes
– 65 data tables and 58 additional tables
– Analyses of the trends in the global market for liquid biopsy research tools, services and diagnostics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029
– Estimates of the market size and revenue growth prospects, along with a market share analysis by application, purpose of analysis, biomarker type, analysis platform (technology type) and region
– Examination of conventional biopsy methods and liquid biopsy enabling technologies
– Discussion of large-scale research initiatives
– Facts and figures pertaining to key market dynamics, technology advances, regulations, and the impact of macroeconomic factors
– Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
– Patent analysis, including key granted and published patents
– Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
– Profiles of leading companies, including Exact Sciences Corp., Natera Inc., Guardant Health, Roche, and NeoGenomics Laboratories
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Liquid Biopsy Versus Traditional Biopsy
Analytes Used in Liquid Biopsy
Emerging Clinical Applications of Liquid Biopsy
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Advances in Liquid Biopsy Workflow Technologies
Increasing Incidence of Cancer
Increasing Awareness of Early Cancer Detection
Limitations of Tissue Biopsy
Market Restraints
Lower Sensitivity of Certain Liquid Biopsy Procedures
Market Opportunities
Growing Significance of Precision Medicine
Emerging Economies such as China
Chapter 4 Emerging Technologies and Clinical Trials
Nanotechnology in Liquid Biopsy
Microfluidic-based Devices in Liquid Biopsy
Clinical Trials in Liquid Biopsy Market
Chapter 5 Market Segmentation Analysis
Market Trends
Segmentation Breakdown
Global Market for Liquid Biopsy by Application
Non-invasive Prenatal Testing (NIPT)
Cancer
Organ Transplantation
Global Market for Liquid Biopsy by Purpose of Analysis
Early Detection/Screening
Monitoring
Diagnosis
Therapy Guidance
Global Market for Liquid Biopsy by Biomarker Type
Cell-free Nucleic Acids
Circulating Tumor Cells
Other Biomarker Types
Global Market for Liquid Biopsy by Analysis Platform
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Other Analysis Platforms
Global Market for Liquid Biopsy by Cancer Site
Pan-Cancer
Colorectal Cancer
Breast Cancer
Lung Cancer
Bladder Cancer
Prostate Cancer
Hematologic Cancer
Gynecologic Cancer
Other Cancers
Geographic Breakdown
Global Market for Liquid Biopsy by Region
North America
Europe
Asia-Pacific
Rest of the World (RoW)
Chapter 6 Competitive Intelligence
Ranking of Leading Players
Comparative Analysis
Chapter 7 Sustainability in the Liquid Biopsy Market: ESG Perspective
Introduction to ESG
ESG Practices in the Liquid Biopsy Industry
Environmental Performance
Social Performance
Governance Performance
ESG Risk Ratings
Concluding Remarks from BCC Research
Chapter 8 Appendix
Methodology
Abbreviations
References
Company Profiles
BIO-RAD LABORATORIES INC.
BIO-TECHNE
DXCOVER LTD.
EXACT SCIENCES CORP.
- HOFFMANN-LA ROCHE LTD.
FREEENOME HOLDINGS INC.
GUARDANT HEALTH
ILLUMINA INC.
MYRIAD GENETICS INC.
NATERA INC.
NEOGENOMICS LABORATORIES
NOVIGENIX SA
PERSONALIS INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
List of Tables
Summary Table B : Global Market for Liquid Biopsy, by Region, Through 2029
Summary Table A : Global Market for Liquid Biopsy, by Application, Through 2029
Table 1 : Liquid Biopsy Sample Types and Characteristics
Table 2 : Types of Analytes Used in Liquid Biopsy
Table 3 : Comparison of ctDNA/cfDNA and CTCs
Table 4 : List of Some Liquid Biopsy-based Available Tests Approved by FDA/CE-IVD
Table 5 : Global Cancer Incidence and Mortality Cases, by WHO Region, 2022
Table 6 : Emerging ctDNA and CTC Technologies for Liquid Biopsies
Table 7 : List of Clinical Trials Conducted in Liquid Biopsies
Table 8 : Global Market for Liquid Biopsy, by Application, Through 2029
Table 9 : Global Market for Liquid Biopsy for NIPT, by Region, Through 2029
Table 10 : Global Market for Liquid Biopsy for Cancer, by Region, Through 2029
Table 11 : Global Market for Liquid Biopsy for Organ Transplantation, by Region, Through 2029
Table 12 : Global Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
Table 13 : Global Market for Liquid Biopsy for Early Detection/Screening, by Region, Through 2029
Table 14 : Global Market for Liquid Biopsy for Monitoring, by Region, Through 2029
Table 15 : Global Market for Liquid Biopsy for Diagnosis, by Region, Through 2029
Table 16 : Global Market for Liquid Biopsy for Therapy Guidance, by Region, Through 2029
Table 17 : Global Market for Liquid Biopsy, by Biomarker Type, Through 2029
Table 18 : Global Market for Liquid Biopsy for Cell-free Nucleic Acids, by Region, Through 2029
Table 19 : Global Market for Liquid Biopsy for Circulating Tumor Cells, by Region, Through 2029
Table 20 : Global Market for Liquid Biopsy for Other Biomarker Types, by Region, Through 2029
Table 21 : Global Market for Liquid Biopsy, by Analysis Platform, Through 2029
Table 22 : Global Market for Liquid Biopsy for Next-Generation Sequencing, by Region, Through 2029
Table 23 : Global Market for Liquid Biopsy for Polymerase Chain Reaction, by Region, Through 2029
Table 24 : Global Market for Liquid Biopsy for Other Analysis Platforms, by Region, Through 2029
Table 25 : Global Market for Liquid Biopsy, by Cancer Site, Through 2029
Table 26 : Global Market for Liquid Biopsy for Pan-Cancer, by Region, Through 2029
Table 27 : Global Market for Liquid Biopsy for Colorectal Cancer, by Region, Through 2029
Table 28 : Global Market for Liquid Biopsy for Breast Cancer, by Region, Through 2029
Table 29 : Global Market for Liquid Biopsy for Lung Cancer, by Region, Through 2029
Table 30 : Global Market for Liquid Biopsy for Bladder Cancer, by Region, Through 2029
Table 31 : Global Market for Liquid Biopsy for Prostate Cancer, by Region, Through 2029
Table 32 : Global Market for Liquid Biopsy for Hematologic Cancer, by Region, Through 2029
Table 33 : Global Market for Liquid Biopsy for Gynecologic Cancer, by Region, Through 2029
Table 34 : Global Market for Liquid Biopsy for Other Cancers, by Region, Through 2029
Table 35 : Global Market for Liquid Biopsy, by Region, Through 2029
Table 36 : North American Market for Liquid Biopsy, by Application, Through 2029
Table 37 : North American Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
Table 38 : North American Market for Liquid Biopsy, by Biomarker Type, Through 2029
Table 39 : North American Market for Liquid Biopsy, by Analysis Platform, Through 2029
Table 40 : North American Market for Liquid Biopsy, by Cancer Site, Through 2029
Table 41 : Estimated Incidence of Cancer Cases in the EU, by Country, 2022
Table 42 : European Research Initiatives Focused on Personalized Medicine
Table 43 : European Market for Liquid Biopsy, by Application, Through 2029
Table 44 : European Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
Table 45 : European Market for Liquid Biopsy, by Biomarker Type, Through 2029
Table 46 : European Market for Liquid Biopsy, by Analysis Platform, Through 2029
Table 47 : European Market for Liquid Biopsy, by Cancer Site, Through 2029
Table 48 : Asia-Pacific Market for Liquid Biopsy, by Application, Through 2029
Table 49 : Asia-Pacific Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
Table 50 : Asia-Pacific Market for Liquid Biopsy, by Biomarker Type, Through 2029
Table 51 : Asia-Pacific Market for Liquid Biopsy, by Analysis Platform, Through 2029
Table 52 : Asia-Pacific Market for Liquid Biopsy, by Cancer Site, Through 2029
Table 53 : RoW Market for Liquid Biopsy, by Application, Through 2029
Table 54 : RoW Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
Table 55 : RoW Market for Liquid Biopsy, by Biomarker Type, Through 2029
Table 56 : RoW Market for Liquid Biopsy, by Analysis Platform, Through 2029
Table 57 : RoW Market for Liquid Biopsy, by Cancer Site, Through 2029
Table 58 : Leading Companies in the Liquid Biopsy Market, 2023
Table 59 : Comparison of Liquid Biopsy Tests for Early Detection of Single Cancers
Table 60 : Key Focus Areas in ESG Metrics
Table 61 : Environmental Performance Initiatives in the Liquid Biopsy Market
Table 62 : Social Performance Initiatives in the Liquid Biopsy Market
Table 63 : Governance Performance Initiatives in the Liquid Biopsy Market
Table 64 : ESG Rankings for Leaders in the Market for Liquid Biopsy, 2024*
Table 65 : Abbreviations Used in this Report
Table 66 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 67 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
Table 68 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 69 : Bio-Rad Laboratories Inc.: News/Key Developments, 2022-2024
Table 70 : Bio-Techne: Company Snapshot
Table 71 : Bio-Techne: Financial Performance, FY 2022 and 2023
Table 72 : Bio-Techne: Product Portfolio
Table 73 : Bio-Techne: News/Key Developments, 2023 and 2024
Table 74 : Dxcover Ltd.: Company Snapshot
Table 75 : Dxcover Ltd.: Product Portfolio
Table 76 : Dxcover Ltd.: News/Key Developments, 2023 and 2024
Table 77 : Exact Sciences Corp.: Company Snapshot
Table 78 : Exact Sciences Corp.: Financial Performance, FY 2022 and 2023
Table 79 : Exact Sciences Corp.: Product Portfolio
Table 80 : Exact Sciences Corp.: News/Key Developments, 2022–2024
Table 81 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 82 : F. Hoffman-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 83 : F. Hoffman-La Roche Ltd.: Product Portfolio
Table 84 : F. Hoffman-La Roche Ltd.: News/Key Developments, 2021–2023
Table 85 : Freenome Holdings Inc.: Company Snapshot
Table 86 : Freenome Holdings Inc.: Product Portfolio
Table 87 : Freenome Holdings Inc.: News/Key Developments, 2023 and 2024
Table 88 : Guardant Health: Company Snapshot
Table 89 : Guardant Health: Financial Performance, FY 2022 and 2023
Table 90 : Guardant Health: Product Portfolio
Table 91 : Guardant Health: News/Key Developments, 2022–2024
Table 92 : Illumina Inc.: Company Snapshot
Table 93 : Illumina Inc.: Financial Performance, FY 2022 and 2023
Table 94 : Illumina Inc.: Product Portfolio
Table 95 : Illumina Inc.: News/Key Developments, 2022 and 2023
Table 96 : Myriad Genetics Inc.: Company Snapshot
Table 97 : Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023
Table 98 : Myriad Genetics Inc: Product Portfolio
Table 99 : Myriad Genetics Inc.: News/Key Developments, 2022-2024
Table 100 : Natera Inc.: Company Snapshot
Table 101 : Natera Inc.: Financial Performance, FY 2022 and 2023
Table 102 : Natera Inc: Product Portfolio
Table 103 : NeoGenomics Laboratories: Company Snapshot
Table 104 : NeoGenomics Laboratories: Financial Performance, FY 2022 and 2023
Table 105 : NeoGenomics Laboratories: Product Portfolio
Table 106 : NeoGenomics Laboratories: News/Key Developments, 2022-2024
Table 107 : Novigenix SA: Company Snapshot
Table 108 : Novigenix SA: Product Portfolio
Table 109 : Novigenix SA: News/Key Developments, 2024
Table 110 : Personalis Inc.: Company Snapshot
Table 111 : Personalis Inc.: Financial Performance, FY 2022 and 2023
Table 112 : Personalis Inc.: Product Portfolio
Table 113 : Personalis Inc.: News/Key Developments, 2023 and 2024
Table 114 : QIAGEN: Company Snapshot
Table 115 : QIAGEN: Financial Performance, FY 2022 and 2023
Table 116 : QIAGEN: Product Portfolio
Table 117 : QIAGEN: News/Key Developments, 2023 and 2024
Table 118 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 119 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 120 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 121 : Thermo Fisher Scientific Inc.: News/Key Developments, 2022
List of Figures
Summary Figure A : Global Market for Liquid Biopsy, by Application, 2021–2029
Summary Figure B : Global Market for Liquid Biopsy, by Region, 2021–2029
Figure 1 : Snapshot of the Market Dynamics for Liquid Biopsy
Figure 2 : Global Market Shares of Liquid Biopsy, by Application 2024
Figure 3 : Global Market for Liquid Biopsy for NIPT, by Region, 2021–2029
Figure 4 : Estimated Number of New Cancer Cases Globally, 2022, 2045 and 2050
Figure 5 : Global Market for Liquid Biopsy for Cancer, by Region, 2021–2029
Figure 6 : Global Market for Liquid Biopsy for Organ Transplantation, by Region, 2021–2029
Figure 7 : Global Market Shares of Liquid Biopsy, by Purpose of Analysis, 2024
Figure 8 : Global Market for Liquid Biopsy for Early Detection/Screening, by Region, 2021–2029
Figure 9 : Global Market for Liquid Biopsy for Monitoring, by Region, 2021–2029
Figure 10 : Global Market for Liquid Biopsy for Monitoring, by Region, 2021–2029
Figure 11 : Global Market for Liquid Biopsy for Therapy Guidance, by Region, 2021–2029
Figure 12 : Global Market Shares of Liquid Biopsy, by Biomarker Type, 2024
Figure 13 : Global Market for Liquid Biopsy for Cell-free Nucleic Acids, by Region, 2021–2029
Figure 14 : Global Market for Liquid Biopsy for Circulating Tumor Cells, by Region, 2021–2029
Figure 15 : Global Market for Liquid Biopsy for Other Biomarker Types, by Region, 2021–2029
Figure 16 : Global Market Shares of Liquid Biopsy, by Analysis Platform, 2024
Figure 17 : Global Market for Liquid Biopsy for Next-Generation Sequencing, by Region, 2021–2029
Figure 18 : Global Market for Liquid Biopsy for Polymerase Chain Reaction, by Region, 2021–2029
Figure 19 : Global Market for Liquid Biopsy for Other Analysis Platforms, by Region, 2021–2029
Figure 20 : Global Market Shares of Liquid Biopsy, by Cancer Site, 2024
Figure 21 : Global Market for Liquid Biopsy for Pan-Cancer, by Region, 2021–2029
Figure 22 : Global Market for Liquid Biopsy for Colorectal Cancer, by Region, 2021–2029
Figure 23 : Global Market for Liquid Biopsy for Breast Cancer, by Region, 2021–2029
Figure 24 : Global Market for Liquid Biopsy for Lung Cancer, by Region, 2021–2029
Figure 25 : Global Market for Liquid Biopsy for Bladder Cancer, by Region, 2021–2029
Figure 26 : Global Market for Liquid Biopsy for Prostate Cancer, by Region, 2021–2029
Figure 27 : Global Market for Liquid Biopsy for Hematologic Cancer, by Region, 2021–2029
Figure 28 : Global Market for Liquid Biopsy for Gynecologic Cancer, by Region, 2021–2029
Figure 29 : Global Market for Liquid Biopsy for Other Cancers, by Region, 2021–2029
Figure 30 : Global Market Shares of Liquid Biopsy, by Region, 2024
Figure 31 : U.S. Elderly Population (65 and Older), 2010–2050
Figure 32 : North American Market for Liquid Biopsy, by Application, 2021–2029
Figure 33 : North American Market for Liquid Biopsy, by Purpose of Analysis, 2021–2029
Figure 34 : North American Market for Liquid Biopsy, by Biomarker Type, 2021–2029
Figure 35 : North American Market for Liquid Biopsy, by Analysis Platform, 2021–2029
Figure 36 : North American Market for Liquid Biopsy, by Cancer Site, 2021–2029
Figure 37 : European Market for Liquid Biopsy, by Application, 2021–2029
Figure 38 : European Market for Liquid Biopsy, by Purpose of Analysis, 2021–2029
Figure 39 : European Market for Liquid Biopsy, by Biomarker Type, 2021–2029
Figure 40 : European Market for Liquid Biopsy, by Analysis Platform, 2021–2029
Figure 41 : European Market for Liquid Biopsy, by Cancer Site, 2021–2029
Figure 42 : Asia-Pacific Market for Liquid Biopsy, by Application, 2021–2029
Figure 43 : Asia-Pacific Market for Liquid Biopsy, by Purpose of Analysis, 2021–2029
Figure 44 : Asia-Pacific Market for Liquid Biopsy, by Biomarker Type, 2021–2029
Figure 45 : Asia-Pacific Market for Liquid Biopsy, by Analysis Platform, 2021–2029
Figure 46 : Asia-Pacific Market for Liquid Biopsy, by Cancer Site, 2021–2029
Figure 47 : RoW Market for Liquid Biopsy, by Application, 2021–2029
Figure 48 : RoW Market for Liquid Biopsy, by Purpose of Analysis, 2021–2029
Figure 49 : RoW Market for Liquid Biopsy, by Biomarker Type, 2021–2029
Figure 50 : RoW Market for Liquid Biopsy, by Analysis Platform, 2021–2029
Figure 51 : RoW Market for Liquid Biopsy, by Cancer Site, 2021–2029
Figure 52 : How a Strong ESG Proposition Benefits Businesses?
Figure 53 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2023
Figure 54 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2023
Figure 55 : Bio-Techne: Revenue Share, by Business Unit, FY 2023
Figure 56 : Bio-Techne: Revenue Share, by Country/Region, FY 2023
Figure 57 : Exact Sciences Corp.: Revenue Share, by Business Unit, FY 2023
Figure 58 : Exact Sciences Corp.: Revenue Share, by Country/Region, FY 2023
Figure 59 : F. Hoffman-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 60 : F. Hoffman-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 61 : Guardant Health: Revenue Share, by Business Unit, FY 2023
Figure 62 : Guardant Health: Revenue Share, by Country/Region, FY 2023
Figure 63 : Illumina Inc.: Revenue Share, by Business Unit, FY 2023
Figure 64 : Illumina Inc.: Revenue Share, by Country/Region, FY 2023
Figure 65 : Myriad Genetics Inc.: Revenue Share, by Business Unit, FY 2023
Figure 66 : Myriad Genetics Inc.: Revenue Share, by Country/Region, FY 2023
Figure 67 : Natera Inc.: Revenue Share, by Country/Region, FY 2023
Figure 68 : NeoGenomics Laboratories: Revenue Share, by Business Unit, FY 2023
Figure 69 : Personalis Inc.: Revenue Share, by Business Unit, FY 2023
Figure 70 : QIAGEN: Revenue Share, by Business Unit, FY 2023
Figure 71 : QIAGEN: Revenue Share, by Country/Region, FY 2023
Figure 72 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 73 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。
ライセンス別価格表
2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
新価格表
ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 4,650 | USD 5,580 | USD 6,696 | USD 8,035 |
ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,950 | USD 3,540 | USD 4,248 | USD 5,098 |
ライセンスタイプ3
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,500 | USD 3,000 | USD 3,600 | USD 4,320 |
旧価格表
旧ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 5,500 | USD 6,600 | USD7.920 | USD 9,504 |
旧ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 3,500 | USD 4,200 | USD 5,040 | USD 6,048 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- 2-5ライセンス
- 同一企業内5名までレポートファイルのご利用が可能です。
- サイトライセンス
- 同一企業同住所内でレポートファイルのご利用が可能です。
- エンタープライズライセンス
- 同一企業内人数無制限でレポートファイルのご利用が可能です。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後3営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- バイオプラスチックの世界市場と技術 2025-03-07
- 半導体製造調査レビュー 2024年 2025-03-06
- 製造市場レビュー 2024年 2025-03-05
- 計測器とセンサの調査レビュー 2024年 2025-03-05
- 航空宇宙用先端材料の世界市場 2025-03-05
